| Having trouble viewing this email? View it as a Web page. 
|  "PNU is a prevention and treatment news summary service. NPIN redistributes summaries as a public service. Inclusion of an article does not constitute CDC endorsement of the content. More details in footer."
|  5/7/2014 | National News  | Hepatitis C Cure in Prison Could Cost Less UNITED STATES :: Viral Hepatitis
Journal Gazette & Times-Courier (05.07.2014) :: By Kurt Erickson | | | The Journal Gazette & Times-Courier reported that a new, highly effective drug used to treat hepatitis C virus (HCV) may not be as expensive as first thought, according to Illinois correctional officials. Prison medical officials examined the drug Sovaldi, made by pharmaceutical company Gilead Sciences, and determined the cost may be less than $6 million next year, down from an originally forecasted $60 million, according to Tom Shaer, Illinois Department of Corrections (IDOC) spokesperson.
The earlier reported figure prompted state Rep. Bill Mitchell (R-Forsyth) to co-sponsor legislation that would prohibit prisons from using the high-cost drug. "I don't care if they use that drug or not, as long as the costs are reasonable," said Mitchell.
While the HCV treatment was welcome, some critics claim the price tag is too high. Shaer argued that the previous cost was “wildly inaccurate” and the state could run into trouble if the law prevented proper medical care to inmates. "We urge those who find unacceptable even extremely limited use of Sovaldi by IDOC, to consider the high cost of lawsuits certain to result from failing to meet our legal obligation to use the most appropriate drug—even in an extremely limited number of cases. Healthcare of inmates is not an IDOC choice. It is a legal and constitutional matter, not a legislative one," Shaer said. |  Read Full Article | Share this Article     | | Back to Top  |  | | International News  | TB Screening Initiative to Focus on Workers of Carpet Factories NEPAL :: TB
Himalayan Times (05.05.2014) | | | The Himalayan Times reported that Nepal’s TB screening initiative that began on March 25 now will include carpet factories in Central Tarai. Prabin Shrestha, programmer and research officer at the Health Research and Social Development Forum, explained that at present they are testing workers in handicraft industries in the capital, but by the third week of May, the vans will be in Bara, Parsa, Chitwan, and Hetauda districts to begin TB screening. On World TB day 2014, the government introduced mobile TB screening outreach to locate people who had never been tested.
The Social Development Forum provides door-to-door TB screening in various parts of the country using two vans equipped with a GeneXpert machine, senior laboratory technicians, and a medical doctor; the National TB Center provides the technical support. The program refers individuals testing positive for TB to the nearest directly observed treatment short course center where the government provides free treatment.
The vans will cover 29 municipalities and 22 districts and screen prisoners, people living in slums, HIV patients and their family members, factory workers, and the mobile population to find unreported cases. The National TB Center reported approximately 10,000 “missing” cases annually and aims to find and treat all patients to meet the target. In 2012–2013, the country treated 35,438 patients. In 2011–2012, Kathmandu had a treatment success rate of 90 percent, which is 5 percent higher than the World Health Organization’s global target. | | Read Full Article | Share this Article | | Back to Top | | | Medical News  | AIDS Death Rates Decreased with Time Since ART Initiation GLOBAL :: HIV/AIDS
Healio (05.02.2014) | | | Healio reported on a study of causes of death among HIV-positive patients receiving antiretroviral therapy (ART). Researchers for the Antiretroviral Therapy Cohort Collaboration reviewed data on patients enrolled in 16 cohorts in Europe and North America. They evaluated and coded the causes of death for the participants who had died and analyzed patient characteristics, time from beginning ART to death, AIDS-defining conditions after ART, and most recent CD4 count.
Of 65,121 patients, 4,237 died, for a mortality rate of 12.9 deaths per 1,000 person-years. Of these, 1,496 died of AIDS, 461 died of a non-AIDS malignancy, and 349 of unnatural causes. Mortality rate decreased from 24.3 per 1,000 person-years in the first 6 months of ART to 10.2 per 1,000 person-years after 5 years of ART for all causes. The decrease is due to fewer AIDS-related deaths, which went from 13.2 per 1,000 person-years in the first 6 months of ART to 2.4 per 1,000 person-years after 5 years.
Results show that cause of death varied based on age, sex, and transmission risk. In the first year of ART, data associated HIV transmission from injection drug use with higher rates of all causes of death compared with men who have sex with men. Also, data associated older age with death from cardiovascular diseases and non-AIDS malignancies. The researchers concluded that further study is required to determine which of various factors connected to HIV or ART are responsible for the results or whether the results are due to aging and non-HIV risk factors. They also suggested larger studies to compare age-standardized mortality rates and risk factors for HIV-positive and -negative populations.
The full report, “Impact of Risk Factors for Specific Causes Death in the First and Subsequent Years of ART Among HIV-Infected Patients,” was published online in the journal Clinical Infectious Diseases (2014; doi: 10.1093/cid/ciu261). | | Read Full Article | Share this Article | | Back to Top | | | | Local and Community News | | News Briefs | | | | |
Since there alot many people complaining about the crack.. Here it is.. The crack will be in english only and will 100% Worked!!! Enjoy :D D...
0 comments:
Post a Comment